Liquidia Corporation (LQDA)

$5.49

+0.18 (+3.39%)
Rating:
Recommendation:
-
Symbol LQDA
Price $5.49
Beta 0.237
Volume Avg. 0.60M
Market Cap 354.078M
Shares () -
52 Week Range 3.26-8.79
1y Target Est -
DCF Unlevered LQDA DCF ->
DCF Levered LQDA LDCF ->
ROE -43.40% Strong Sell
ROA -26.01% Sell
Operating Margin -
Debt / Equity 39.50% Neutral
P/E -6.86 Strong Sell
P/B 3.72 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest LQDA news


Mr. Neal Fowler
Healthcare
Biotechnology
NASDAQ Capital Market

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.